Market Overview

UPDATE: Jefferies Raises PT on Merck & Co. on Positive Outlook

Related MRK
KEYTRUDA® (pembrolizumab) Receives New Draft Recommendation from National Institute for Health and Care Excellence (NICE) in U.K. for First-Line Treatment for Advanced Melanoma
Agilent Company Dako, Announces FDA Approval of New Companion Diagnostic for Lung Cancer
Bristol-Myers drug approved (Investor's Business Daily)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Hold rating on Merck & Co. (NYSE: MRK), and raised the price target from $46.00 to $48.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Merck & Co. closed on Tuesday at $45.51.

Latest Ratings for MRK

Sep 2015JP MorganMaintainsOverweight
Aug 2015JefferiesMaintainsHold
Aug 2015BMO CapitalUpgradesMarket PerformOutperform

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings


Related Articles (MRK)

Get Benzinga's Newsletters